13 recruiting. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Recruiting 13 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Teprotumumab N01, Methylprednisolone - Thyroid Eye Disease | Phase 4 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 92 | 2026-07-30 | 2026-08-13 |
| Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery Dexmedetomidine, Standard General Anesthesia - Thyroid Diseases | Phase 4 | Recruiting | Bach Mai Hospital | 100 | 2026-04-13 | 2026-04-15 |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Sore Throat After Open Neck Elective Surgery Hydrocortisone Acetate 1% Ointment, Lidocaine hydrochloride 0,05% with chlorhexidine - Postoperative Sore Throat, Cough, Hoarseness, Thyroid and Parathyroid Surgery | Phase 4 | Recruiting | Saint Petersburg State University, Russia | 764 | 2025-09-15 | 2026-04-13 |
| Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO IBI311, Follew-up - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 50 | 2025-04-15 | 2025-09-03 |
| Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 96 | 2025-04-15 | 2025-09-03 |
| The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 64 | 2025-04-10 | 2025-09-03 |
| A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg) - Thyroid-Associated Ophthalmopathy | Phase 4 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 60 | 2024-12-12 | 2025-04-16 |
| Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo - Thyroid Nodule | Phase 4 | Recruiting | Xintian Pharmaceutical | 234 | 2024-07-30 | 2026-03-24 |
| The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response bilateral ultrasound guided intermediate cervical plexus block with 0,25% levobupivacaine - Thyroid Cancer, Thyroid and Parathyroid Surgery | Phase 4 | Recruiting | University Hospital Dubrava | 48 | 2024-05-13 | 2026-06-16 |
| Dosing of LT4 in Older Individuals Levothyroxine Sodium - Hypothyroidism | Phase 4 | Recruiting | University of Pennsylvania | 228 | 2024-01-31 | 2026-02-19 |
| Preoperative Corticosteroids in Autoimmune Thyroid Disease Dexamethasone, Placebo - Graves Disease, Hashimoto Disease | Phase 4 | Recruiting | Indiana University | 76 | 2023-06-16 | 2026-08-05 |
| Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease Methimazole - Graves Disease, Relapse | Phase 4 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 240 | 2018-05-01 | 2023-12-11 |
Graves Ophthalmopathy (5) · Insulin-Like Growth Factor I, Resistance To (3) · Graves Disease (2) · Thyroid Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Cough (1) · Emergence Delirium (1) · Goiter (1) · Hashimoto Disease (1) · Hoarseness (1) · Hypothyroidism (1) · Neoplasms (1) · Postoperative Nausea and Vomiting (1) · Recurrence (1)
Endocrine System Diseases (13) · Autoimmune Diseases (7) · Exophthalmos (7) · Eye Diseases (7) · Goiter (7) · Hyperthyroidism (7) · Immune System Diseases (7) · Orbital Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Eye Diseases, Hereditary (5) · Genetic Diseases, Inborn (5) · Graves Disease (5) · Endocrine Gland Neoplasms (3) · Head and Neck Neoplasms (3)
Glucocorticoids (2) · Chlorhexidine (1) · Control Groups (1) · Cytochrome P-450 CYP2C8 (1) · Cytochrome P-450 CYP3A (1) · Dexamethasone (1) · Dexmedetomidine (1) · Methimazole (1) · Methylprednisolone (1) · Ointments (1) · Thyroxine (1) · flupentixol, melitracen drug combination (1) · hydrocortisone acetate (1) · pralsetinib (1) · tocilizumab (1)
Shanghai Changzheng Hospital (3) · Bach Mai Hospital (1) · Indiana University (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Rigel Pharmaceuticals (1) · Saint Petersburg State University, Russia (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University Hospital Dubrava (1) · University of Pennsylvania (1) · Xintian Pharmaceutical (1)
China (7) · United States (2) · Croatia (1) · Russia (1) · Spain (1) · Vietnam (1)
Alexandria McDow, MD (1) · Anne R. Cappola, M.D., Sc.M. (1) · Qin Li (1) · Sergey M. Efremov, MD, PhD (1) · Tao Yang (1) · Thang Toan Nguyen, MD, PhD, Assoc Prof (1) · Xuqin Zheng (1) · Yingli Lu (1)
R01AG081698 (1)